It is made available under a CC-BY-NC-ND 4.0 International license .

1 The aerobiology of SARS-CoV-2 in UK hospitals and the impact of aerosol generating

2 procedures

- 3 Susan Gould^{1*}, Rachel L Byrne^{1*}, Thomas Edwards¹, Ghaith Aljayyoussi¹, Dominic Wooding¹,
- 4 Kate Buist¹, Konstantina Kontogianni¹, Allan Bennett², Barry Atkinson², Ginny Moore², Jake
- 5 Dunning ³, Stacy Todd ⁴, Marie-Claire Hoyle⁴, Lance Turtle ⁵, Tom Solomon ^{4,5,6,7}, Richard
- 6 Fitzgerald ⁵, Mike Beadsworth ⁴, Paul Garner ¹, Emily R Adams ¹, and Tom Fletcher ^{1,4}
- 7 ¹Liverpool School of Tropical Medicine, Liverpool, UK.
- 8 ²UK Health Security Agency
- 9 ³University of Oxford
- 10 ⁴Liverpool University Hospitals NHS Foundation Trust
- ⁵University of Liverpool
- ¹² ⁶National Institute for Health Research Health Protection Research Unit in Emerging and
- 13 Zoonotic Infections, Institute of Infection, Veterinary and Ecological Sciences, University of
- 14 Liverpool
- ⁷The Walton Centre NHS Foundation Trust
- 16 *authors contributed equally
- 17 Running title: SARS-CoV-2 aerosols in AGP rooms (max 50 characters)
- 18 **Sources of funding:** SG, EA, JD, LT, TS and TF are supported by the National Institute for Health
- 19 Research (NIHR) Health Protection Research Unit in Emerging and Zoonotic Infections. SG and
- PG are supported by the READ-It (project number 300342-104) which is funded by UK aid from
- 21 the UK government. PhD stipend from the medical research council to RLB.
- 22 **Conflicts of Interest:** Emily Adams is Director of Epidemics and NTDs at Global Access diagnostics.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 23 Corresponding author: Rachel L Byrne, Liverpool School of Tropical Medicine, Pembroke Place,
- Liverpool UK. E-mail: Rachel.byrne@lstmed.ac.uk phone number: 01517053100
- 25 **Keywords:** COVID-19, aerobiology, Aerosol generating procedure
- 26 Word count: Abstract, 250; Manuscript, 3047
- 27 **Authors' contributions**: The study was conceived by ERA, RLB, TF and SG. The study design was
- developed by ERA, BA, AB, RLB, TE, TF, SG and GM. Data collection and extraction was
- 29 conducted by RLB, SG, MH. Laboratory work was completed by KB, RLB, SG, KK and DW. Data
- analysis and interpretation were conducted by GA, BA, MB, AB, RLB, JD, TE, RF, TF, PG, SG, GM,
- 31 TS, ST, LT and DW. The initial manuscript was prepared by GA, RLB and SG. All authors edited
- 32 and approved the final manuscript.

It is made available under a CC-BY-NC-ND 4.0 International license .

33 Abstract (250 words)

34 Background

SARS-CoV-2 nosocomial transmission to patients and healthcare workers (HCWs) has occurred
 throughout the COVID-19 pandemic. Aerosol generating procedures (AGPs) seemed particularly
 risky, and policies have restricted their use in all settings. We examined the prevalence of
 aerosolized SARS-CoV-2 in the rooms of COVID-19 patients requiring AGP or supplemental
 oxygen compared to those on room air.

40 Methods

41 Samples were collected prospectively near to adults hospitalised with COVID-19 at two tertiary

42 care hospitals in the UK from November 2020 – October 2021. The Sartorius MD8 AirPort air

43 sampler was used to collect air samples at a minimum distance of 1.5 meters from patients. RT-

44 qPCR was used following overnight incubation of membranes in culture media and extraction.

45 Results

46 We collected 219 samples from patients' rooms: individuals on room air (n=67), receiving

47 oxygen (n=65) or AGP (n=67). Of these, 54 (24.6%) samples were positive for SARS-CoV-2 viral

48 RNA. The highest prevalence was identified in the air around patients receiving oxygen (32.3%,

49 n=21, Cl95% 22.2 to 44.3%) with AGP and room air recording prevalence of (20.7%, n=18,

50 Cl95% 14.1 – 33.7%) and (22.3%, n=15, Cl95% 13.5 – 30.4%) respectively. We did not detect a

51 significant difference in the observed frequency of viral RNA between interventions.

52 Interpretation

53 SARS-CoV-2 viral RNA was detected in the air of hospital rooms of COVID-19 patients, and AGPs

54 did not appear to impact the likelihood of viral RNA. Enhanced respiratory protection and

appropriate infection prevention and control measures are required to be fully and carefully

56 implemented for all COVID-19 patients to reduce risk of aerosol transmission.

It is made available under a CC-BY-NC-ND 4.0 International license .

57 Background

Since the emergence of the severe acute respiratory syndrome coronavirus (SARS-CoV-2) in 2019 there have been intense efforts to understand the natural history of COVID-19 disease and transmission characteristics. The risk of nosocomial transmission has been well reported and personal protective equipment (PPE) requirements for healthcare workers (HCWs) has generated significant discussion internationally ¹. The World Health Organization (WHO) recently estimated that between 80 000 and 180 000 HCWs have died of COVID-19 up to May 2021².

65 Aerosol generating procedures (AGPs) such as non-invasive ventilation (NIV) have been 66 considered essential in providing respiratory support for patients with severe COVID-19 and in reducing the need for invasive ventilation which is associated with higher morbidity and 67 68 mortality, others such as High Flow oxygen have now been shown to offer no benefit in comparison with conventional oxygen³⁻⁵. Despite improved patient outcomes, AGPs came 69 under increased scrutiny during the severe acute respiratory syndrome (SARS) outbreak of 70 2003, when observational data suggested AGPs increased the risk of healthcare workers (HCW) 71 acquiring infection⁶. Hesitancy in adopting NIV, high flow oxygen or performing other AGPs may 72 be attributable to perceived risk to HCWs or limited availability of resources thought to be pre-73 requisite such as negative pressure ventilation and higher-grade PPE⁷. In addition, there is a 74 lack of consensus as to what classes as an AGP and international guidelines (such as WHO, the 75 76 Centers for Disease Control (CDC) or UK Health Security Agency (UK HSA)) are based on expert 77 opinion due to a lack of solid evidence base.

Air sampling studies in healthcare settings have reported a broad range of frequencies of
detection of SARS-CoV-2. Multi-centre environmental sampling performed by UK HSA in 2020
in 8 UK hospitals identified SARS-CoV-2 RNA in 4 of 55 air samples collected <1m from patients⁸.
Other studies have reported rates of 0-72%^{9,10} PCR positivity in air samples. More recent
environmental sampling within the RECOVERY-RS (Randomised Evaluation of COVID-19
Therapy, Respiratory Support) study included air samples collected during administration of
continuous positive airways pressure (CPAP), high flow nasal oxygen (HFNO) and supplemental

It is made available under a CC-BY-NC-ND 4.0 International license .

oxygen. Of 90 air samples from 30 patients 14% were positive for at least one target on PCR and
 no statistical difference in frequency of positivity was identified between the three groups
 (CPAP, HFNO and other oxygen)¹¹. In healthy volunteers, two studies have demonstrated that
 coughing, speaking or heavy breathing generate significantly higher volumes of detectable
 respiratory particles than use of CPAP or HFNO^{12,13}.

90 However, confirmation of the significance of SARS-CoV-2 in the air in hospitalised settings has

not been definitive due to the absence of routine air sampling in a prospective COVID-19

patient cohort, with the WHO calling for further studies on the risk of SARS-CoV-2 release

93 during AGPs⁷. A range of approaches have been adopted to investigate the relative risk of

94 aerosol transmission in comparison to other modes like fomite, direct contact or close-range

95 droplet¹⁴. Further, there is a recognized need to identify which precautions would be most

96 effective in mitigating risks, to better protect communities and healthcare services including

97 vulnerable patients and staff.

98 This study addresses the question of whether there is an increased likelihood of detecting

99 aerosolized SARS-CoV-2 RNA in the rooms of COVID-19 patients undergoing AGPs than in the

rooms of patients requiring oxygen at flow rates of less than 15 L/min via mask or nasal

101 cannulae, or not requiring any supplemental oxygen. For the purposes of this study, AGPs are

102 defined as those listed by UKHSA for which specific guidance on infection prevention and

103 control (IPC) measures is provided in the UK (UKHSA 2022)¹⁵ (Figure 1).

104 Figure 1: List of procedures defined as aerosol generating procedures (UKHSA)

- 105 *Tracheal intubation and extubation • 106 Manual ventilation • 107 Tracheotomy or tracheostomy procedures (insertion or removal) • 108 *Bronchoscopy • 109 Dental procedures (using high speed devices, for example ultrasonic scalers/high speed drills) • 110 *Non-invasive ventilation (NIV); bi-level positive airway pressure ventilation (BiPAP) and continuous • 111 positive airway pressure ventilation (CPAP) 112 • *High flow nasal oxygen (HFNO) High frequency oscillatory ventilation (HFOV) 113 Induction of sputum using nebulised saline 114 •
- Respiratory tract suctioning
- Upper ear, nose, and throat (ENT) airway procedures that involve respiratory suctioning

It is made available under a CC-BY-NC-ND 4.0 International license .

117 118 110	•	*Upper gastro-intestinal endoscopy where open suction of the upper respiratory tract occurs beyond the oro-pharynx
120	•	*indicates procedures included in this study

121 Methods (781)

122 Setting

123 Liverpool University Hospitals NHS Foundation Trust have two acute tertiary referral hospital sites within Liverpool, UK (Royal Liverpool University (RLUH) and Aintree University Hospitals 124 (AUH)) that have each managed large cohorts of COVID-19 patients. CPAP, non-invasive 125 ventilation and use of high-flow oxygen were rapidly adopted as therapeutic interventions in 126 Liverpool¹⁶ but are listed as AGPs. AGPs were conducted in areas with enhanced ventilation, 127 128 including pre-existing negative pressure rooms, newly installed temporary systems providing ventilation or areas such as theatre or intensive care. Together with UK-HSA, who had already 129 undertaken air and environmental sampling in hospitals⁸ we continued to collect air samples 130 from the rooms of patients hospitalised with COVID-19. 131

132 Prospective air sampling was performed around inpatients with a recent diagnosis of SARS CoV-2 and in community ambulatory cases (n=13) admitted to the clinical research unit for 133 134 screening or treatment as part of an early phase trial. Samples included in this interim analysis were collected between November 2020 and October 2021, and the dominant circulating 135 variants in the UK during this period were B.1.1.7 Alpha (PANGO lineage B.1.1.7) and Delta 136 (PANGO lineage B.1.617.2)¹⁷. Locations sampled include high dependency units, NIV units, 137 138 critical care units, infectious diseases, respiratory and general wards, and emergency departments. 139 No additional biological samples or clinical information were collected from the patients whose rooms was sampled. No changes to behaviour or clinical care were requested from staff or 140 141 patients during sampling periods, staff and patients were aware that sampling was taking place. Samples were categorised as either 1) room samples; patients not undergoing any respiratory 142 treatment 2) oxygen; patients undergoing oxygen at flow rates of less than 15L/min via nasal 143 144 cannulae/mask or 3) AGP; patients undergoing an AGP.

It is made available under a CC-BY-NC-ND 4.0 International license .

145 Sample collection and processing

To collect air samples, we used the Sartorius MD8 AirPort portable air sampler with gelatin membranes (Sartorius, Germany). To ensure aerosols were captured and to minimize the collection of large droplets, the sampler was placed at approximately 1.5 meters¹⁸ and the sampler faced away from the participant. When sampling at a participant's bedside, the sampler was typically placed on a hospital chair or table. At each sampling timepoint 1000L of air was collected at a flow rate of 40 L/min.

Once completed the gelatin membrane was removed from the sampler using clean gloves, and 152 153 placed in a sterile 50ml Falcon tube (Corning Science, United States). Samples were transported 154 to the Biological Safety level 3 (BSL3) laboratories at the Liverpool School of Tropical Medicine within 2 hours of sample collection. The gelatin membranes were immediately suspended in 155 156 10ml Dulbecco's modified Eagle's medium (DMEM) with 10% fetal bovine solution (FBS; both 157 ThermoFisher, USA) and 50 units per ml of penicillin/streptomycin (Gibco, US). Samples were vortexed and then stored overnight at 4°C to allow the membrane to fully dissolve without 158 impacting the stability of SARS-CoV-2¹⁹. 159

160 **RNA extraction, PCR and cell culture**

Following overnight storage, samples were brought to room temperature by incubation for up
to two hours. 140µl (1.4%) of each sample was then taken for RNA extraction. Viral RNA was
extracted using the QIAamp viral RNA mini kit (Qiagen, Germany) following the manufacturer's
instructions with an internal RT-qPCR extraction control incorporated before the lysis stage
(ThermoFisher, USA). Once extracted samples were taken immediately for downstream
application and stored at 4°C during PCR setup.

For SARS-CoV-2 RT-qPCR detection, 10µl of extracted RNA was tested using the TaqPath™
COVID-19 CE-IVD RT-PCR assay (ThermoFisher, USA) that detects three different SARS-CoV-2
genomic regions (ORF1ab, N gene, S gene), on the QuantStudio 5 platform (ThermoFisher,
USA). The PCR was deemed to be positive if one SARS-CoV-2 target and the internal control
amplified, this differs from the manufacturer instructions whereby two SARS-CoV-2 targets

It is made available under a CC-BY-NC-ND 4.0 International license .

must amplify however this is for clinical samples rather than for environmental samples. We do not infer viability of the viral RNA we detected and thus the presence/absence of viral RNA is recorded here. In instances of low Ct values the third target can often be out competed and thus viral load calculations have not been appropriate using this assay. Samples were negative if only the internal extraction control amplified.

177 Cell culture was attempted using a methodology adapted from Edwards *et al* ²⁰. For samples
178 identified as the Alpha variant, based on S gene deletion, a 5-day incubation post inoculation
179 was used due to the variant's slower growth rate and smaller plaque sizes in Vero E6 cells ²¹.
180 For all other samples a 3-day post inoculation incubation was utilized, as is routine laboratory
181 procedure. After three passage events, samples were fixed with 10% formalin, stained using
182 crystal violet and visually inspected for viral plaques.

183 Statistical Analysis

All data handling and manipulation was performed through R 3.6.3²². Binomial generalized linear models (GLM) were performed to assess the ability of procedure to detect a positive result, with time since infection, cycle threshold (Ct) value and location of patient included as co-variates. Chi-Square test was performed to estimate the effect of procedure on detecting a positive result in isolation from other factors. Additionally one-way ANOVA tests were performed to assess quantitative differences between Ct values among different methods for each gene.

191 Ethics and Approvals

This study was performed in conjunction with UK HSA as part of the COVID-19 clinical response. In line with UK Health Resource Authority guidance this was performed as a service evaluation and consisted of environmental sampling and simplified and anonymized routinely collected patient information. The environmental sampling process was explained to patients and verbal consent obtained.

197 Results (450)

It is made available under a CC-BY-NC-ND 4.0 International license .

- 198 A total of 219 air samples were collected during this study from bed spaces of 199 individuals
- 199 (with some patient sampled at more than one timepoint) either on room air only (n=67),
- receiving supplemental oxygen (n=65) or undergoing an AGP (n=87) (Table 1).
- 201 Table 1: Procedures sampled, and frequency of positive results observed

Aerosol genera	ating procedures	Non-aerosol generating procedures			
Procedure	percent positive (n/N)	Procedure	percent positive (n/N)		
CPAP hood or mask	19.2% (10/52)	Room air	24.6% (17/69)		
BiPAP	0% (0/3)	Oxygen - Nasal cannulae	28.6% (8/28)		
Hi Flow oxygen (mask or nasal)	14.3% (3/21)	Oxygen – Venturi mask	33.3% (9/27)		
Intubation	100.0% (1/1)	Oxygen – NRB	20.0% (1/5)		
Bronchoscopy	100.0% (2/2)	Other/Not known	75% (3/4)		
Endoscopy	50.0% (1/2)				
All	20.9% (17/81)		28.6% (38/133)		

202 203 CPAP Continuous positive airway pressure. BiPAP Bilevel Positive Airway Pressure. NRB Non-rebreathe.

204

The median number of days since onset of symptoms was 7 (Table 2). In total, 24.7% (n=55,

206 CI95% 19.4-30.8%) were positive for SAR-CoV-2 viral RNA (Appendix 1). The highest prevalence

was identified in the air around patients who were receiving oxygen (32.3%, n=21, Cl95% 22.2

to 44.3%) with AGP and room air recording prevalence of 20.7% (n=18, Cl95% 14.1 - 33.7%) and

209 22.3% (n=15, CI95% 13.5 – 30.4%) respectively, as shown in figure 2. The likelihood of a sample

210 being PCR positive was not influenced by procedure (GLM, p >0.05).

Table 2: Number of days between onset of symptoms and sample collection within each group

	AGP	Oxygen	Room air	All
Median number of	10 (1-27)	7 (0-42)	5 (1-12)	7(0-42)
days since onset of				
symptoms				
Onset of symptoms	5	2	1	8
unknown				
Asymptomatic	2	1	17	20

212 AGP Aerosol generating procedure.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 213 We did not detect a difference in Ct values for positive samples between procedure (p>0.05,
- one-way ANOVA), shown in figure 3. We observed a reduced detection of S gene, indicative of
- Alpha variant presence, compared to other RT-qPCR genomic targets (ORF1 and N gene). Mean
- 216 Ct values for AGPs, Oxygen and Room air were 32.18, 33.08 and 33.88 respectively and cell
- 217 culture for each sample was negative.



218

Figure 2: The percentage of samples PCR positive for SARS-CoV-2 viral RNA collected from the rooms of PCR

220 positive patients in two Liverpool Hospitals. There was no statistically significant difference between aerosol

generating procedures (AGP), oxygen or room air and the likelihood of detecting viral RNA (GLM, p>0.05). N.s.

indicates no statistical difference between the three methods (one-way ANOVA, p>0.05).

It is made available under a CC-BY-NC-ND 4.0 International license .



223

Figure 3: The cycle threshold (Ct) value of SARS-CoV-2 positive samples for each procedure (aerosol generating
 procedure and oxygen) and room air. The PCR used utilize three distinct regions of the SARS-CoV-2 genome
 (ORF1, Nucleocapsid (N) gene and spike (S) gene). It is important to note that the alpha variant has significant
 mutations in the s gene is not detectable, resulting in fewer data points. N.s. indicates no statistical difference
 between the three methods for each gene (one-way ANOVA, p>0.05).

229 We did not detect an effect of the number of days since reported onset of symptoms and the

- frequency of detection of viral RNA or Ct values (GLM, P> 0.05). Further, no association
- 231 between RT-qPCR results and sampling location e.g., emergency department or critical care unit
- was identified (GLM, p>0.05). Of note, there was no obvious difference in positive results for

It is made available under a CC-BY-NC-ND 4.0 International license .

- the Oxygen or Room air groups when sampling in standard ventilation areas rather than
- enhanced ventilation areas (RR in Oxygen group 1.22, RR in Room Air group 1.08) (Table 3).

Table 3: Type of ventilation, estimated air changes (ACH) and frequency of observed positive PCR results in each
 group

Type of ventilation	Estimated air	Intervention				
	changes	Oxygen	AGP	Room air only		
Neutral pressure	6	9/25	0/0	8/39		
Negative Pressure	12	10/34	15/66	4/21		
Unknown		2/6	0/3	0/2		
ITU/Theatre	10	0/0	3/12	0/0		

237

ITU Intensive Therapy Unit, AGP Aerosol generating procedure

238 An additional 16 air samples were taken in areas either occupied or used by patients with confirmed SARS-CoV-2 infection (e.g. bathroom, nursing station), or directly adjacent i.e. 239 240 considered to be at risk of contamination (appendix 1), SARS-CoV-2 RNA was detected in 5 of 241 these. Culture was negative, and fungal overgrowth was noted in the bathroom samples. Of 4 samples collected in shared patient bathrooms 2 were RNA positive, as were 2 of 8 collected at 242 243 nursing stations, the remaining positive sample was collected in an ITU bay. Five of the nursing 244 station samples were from stations within 'red' zones, 1 from an area adjacent to a red zone, 245 and 2 from ward nursing stations more than 3 metres from COVID-19 patient rooms with separating doors. The Ct values of these 5 samples ranged from 22.4 (S gene) at a nursing 246 station where sample was positive for all 3 genes tested, to 35.19 (for only one gene) for the 247 248 second positive nursing station sample and patient bathrooms. The positive sample collected in 249 a COVID-19 bay (with the nearest patient intubated) was positive for N gene and ORF1 genes.

250 **Discussion**

The factors that facilitate nosocomial transmission of SARS-CoV-2 remain incompletely understood, including any additional risks posed by AGPs. To improve understanding and inform IPC recommendations we have undertaken the largest air sampling study for SARS-Cov-2 published to date. In this report we provide evidence for the presence of SARS-CoV-2 viral RNA isolated from the air of clinical environments in UK hospitals. In line with previous reports^{23,24}, we found Ct values to be high (typically above 30), indicative of low viral loads present. We did

It is made available under a CC-BY-NC-ND 4.0 International license .

not record any significant difference in the observed frequency of viral RNA detection nor viral
load between different procedures being undertaken including AGPs. Interestingly, we did
observe higher positivity rates in individuals receiving oxygen (flow rates of less than 15 L/min
via nasal cannulae) than either AGP patients or those without supplementary oxygen although
not statistically significant.

The viral dynamics of SARS-CoV-2 in human disease is now well reported with higher viral loads 262 and transmission risk predominantly occurring earlier in disease course. Commonly used AGPs 263 such as CPAP are usually required later in the clinical course with median time from onset of 264 symptoms to development of respiratory failure being 8-12 days²⁸. However, we did not see a 265 266 significant relationship between time since symptom onset and likelihood of viral RNA 267 detection. Infective SARS-CoV-2 virus is rarely identified from clinical samples beyond 9 days from onset of symptoms²⁶ and thereby chances of capturing viable virus may be confounded. 268 We were unable to culture samples, likely due to the high Ct values observed, dilutional effect 269 270 and due to the challenges in culturing virus after potential desiccation during the methods of air sampling. Two reports describe the isolation of infectious SARS-CoV-2 from air sampling. 271 Lednicky et al describe isolation of SARS-CoV-2 virus from hospital rooms used by 2 patients 272 and a vehicle occupied by an infected individual with sequencing of cultured virus matching 273 that of the cases sampled^{27,28}. Another challenge in isolating virus from air samples was 274 identified by Lednicky et al as another respiratory virus was found to potentially overgrow 275 SARS-CoV-2 in culture²⁷. Santarpia *et al* described cytopathic effect (CPE), suggested increase in 276 RNA titre on days 3 and 4 of culture and presence of viral proteins on immunofluorescent 277 staining in 1 air sample but could not confirm cultivation of virus²⁴. Published aerobiology 278 studies in healthcare settings use a wide array of methods such as filtering air through gelatin, 279 PTFE or PC membranes, using liquid cyclonic sampling such as the Coriolis (Bertin), or impaction 280 281 e.g., Anderson samplers (Appendix 2). Sampling distances from specified patients sampled varied from 10cm to 3m. Lednicky et al utilised a water condensation collection method (VIVAS) 282 and Santarpia the Sartorius MD8 airport sampler with gelatin membrane filters^{24,27}. The 283 diversity of study design and equipment as well as processing and analytical methods presents 284 challenges in comparing the results of different studies. Less than 10 air sampling studies 285

It is made available under a CC-BY-NC-ND 4.0 International license .

identified through literature search have reported attempted cell culture^{10,11,27,29-31}, and the
majority have been unable to confirm presence of viable virus despite detection of SARS CoV-2
RNA through PCR^{11,29,31}. This is likely attributable to the insensitivity of cell culture, which
requires a large inoculum and represents an imperfect model of infection of the human
nasopharynx. These challenges are increased when considering environmental samples with
low concentrations of detectable viral RNA and the degree of dilution involved in air sampling
methods including our own.

293 It is now accepted that a spectrum of expelled sizes of respiratory particles exist with risk of infection dependent on additional key factors. These include variables relating to the person 294 295 (e.g., symptoms, duration of illness, individual variation in respiratory particle dispersion) and 296 those related to place (e.g., ventilation, proximity to susceptible individuals) that may be 297 equally or more important than the procedures undertaken. As this was a pragmatic environmental sampling study, detailed patient level data and correlation with clinical SARS 298 CoV-2 samples was not available. This is a recognized limitation as individual characteristics and 299 300 the viral load detectable on clinical samples may impact likelihood of detection of viral RNA or viable virus in the environment. AGPs were conducted in negative pressure single rooms, pods 301 302 or bays and bronchoscopy or endoscopy in designated facilities in accordance with Health 303 Technical memorandum 03-01 (including minimum 10 air changes per hour). Those on room air 304 or oxygen were more commonly cared for in rooms with neutral pressure. We also recognise that multiple factors affect the potential impact of infective aerosols including temperature, 305 306 humidity and ventilation, patient and staff behaviour and pre-existing natural or vaccine mediated immunity. 307

This study adds to the data of air sampling studies conducted within hospitals caring for COVID-19 patients and offers reassurances to HCW performing AGPs that the presence of SARS-CoV-2 in the air is no different compared with environments where no AGPs are taking place. Our data supports the conclusions drawn from the recent exploratory air sampling study conducted on 30 participants within the RECOVERY RS trial in which CPAP, HFNO and supplementary oxygen

It is made available under a CC-BY-NC-ND 4.0 International license .

via venturi were compared. The observed frequency of detection was not significantly higher in
 the AGP groups¹¹.

Internationally differing lists of AGPs have been produced e.g. including or excluding nebulized 315 316 therapies or cardiopulmonary resuscitation. In the UK the expert panel responsible for formulating such a list assessed the available evidence as 'poor quality'¹⁵. AGPs vary widely and 317 more sampling around a broader range of procedures is required to establish whether there is 318 any evidence of increased risk associated. Any reduction in protections for potentially 319 vulnerable staff or patients regarding AGPs would require more certainty which could only be 320 provided by a more comprehensive evidence base. As we move towards endemicity of COVID-321 322 19, it remains imperative to protect HCW and vulnerable patients from nosocomial infections. 323 Appropriate PPE and mask use are essential as SARS-CoV-2 is frequently detectable in the air 324 surrounding positive patients. We believe our data supports the use of FFP2/3 medical masks for HCWs caring for COVID-19 patients, particularly for those with prolonged contact in line 325 with HSE guidelines ¹⁵. As we move forwards, we must continue to avoid oversimplifying the 326 transmission dynamics of SARS-CoV-2 including into 'droplet vs aerosol', as this can lead to 327 fixed IPC recommendations and must now appreciate that the 'person, place and procedure' 328 influence transmission risk. Future recommendations must be guided by emerging evidence 329 330 including ongoing studies to identify transmission differences that may occur with new variants of concern. 331

332 Role of the funding source

333 The study funders had no influence over the design, conduct, analysis and interpretation of the 334 study; nor the writing of the report and the decision to submit the paper for publication.

It is made available under a CC-BY-NC-ND 4.0 International license .

335 **References**

336	1	Thomas JP, Srinivasan A, Wickramarachchi CS, Dhesi PK, Hung YMA, Kamath A V.
337		Evaluating the national PPE guidance for NHS healthcare workers during the COVID-19
338		pandemic. Clin Med J R Coll Physicians London 2020; 20: 242–7.
339	2	World Health Organisation. Health and Care Worker Deaths during COVID-19. 2021.
340		https://www.who.int/news/item/20-10-2021-health-and-care-worker-deaths-during-
341		covid-19 (accessed Oct 21, 2021).
342	3	Wozniak DR, Rubino A, Tan AL, et al. Positive role of continuous positive airway pressure
343		for intensive care unit patients with severe hypoxaemic respiratory failure due to COVID-
344		19 pneumonia: A single centre experience. <i>J Intensive Care Soc</i> 2022; 23 : 27–33.
345	4	Ashish A, Unsworth A, Martindale J, et al. CPAP management of COVID-19 respiratory
346		failure: A first quantitative analysis from an inpatient service evaluation. BMJ Open Respir
347		<i>Res</i> 2020; 7 : e000692.
348	5	Perkins GD, Ji C, Connolly BA, et al. Effect of Noninvasive Respiratory Strategies on
349		Intubation or Mortality among Patients with Acute Hypoxemic Respiratory Failure and
350		COVID-19: The RECOVERY-RS Randomized Clinical Trial. JAMA - J Am Med Assoc 2022;
351		327 : 546–58.
352	6	Judson SD, Munster VJ. Nosocomial transmission of emerging viruses via aerosol-
353		generating medical procedures. Viruses. 2019; 11 . DOI:10.3390/v11100940.
354	7	Diaz, Janet; Appiah, John; Askie, Lisa; Baller, April; Banerjee, Anshu; Barkley, Shannon;
355		Bertagnolio, Silvia; Hemmingsen, Bianca; Bonet, Mercedes; Cunningham J. COVID-192:
356		Clinical management Living guidance. 2021
357		https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (accessed
358		Sept 6, 2021).
359	8	Moore G, Rickard H, Stevenson D, et al. Detection of SARS-CoV-2 within the healthcare

It is made available under a CC-BY-NC-ND 4.0 International license .

environment: a multi-centre study conducted during the first wave of the COVID-19 360 361 outbreak in England. J Hosp Infect 2021; 108: 189–96. Li YH, Fan YZ, Jiang L, Wang HB. Aerosol and environmental surface monitoring for SARS-362 9 CoV-2 RNA in a designated hospital for severe COVID-19 patients. *Epidemiol Infect* 2020. 363 DOI:10.1017/S0950268820001570. 364 365 10 Ang AXY, Luhung I, Ahidjo BA, et al. Airborne SARS-CoV-2 surveillance in hospital environment using high-flowrate air samplers and its comparison to surface sampling. 366 367 *Indoor Air* 2021; : 1–10. Winslow RL, Zhou J, Windle EF, et al. SARS-CoV-2 environmental contamination from 368 11 hospitalised patients with COVID-19 receiving aerosol-generating procedures. *Thorax* 369 2021; : thoraxjnl-2021-218035. 370 Wilson NM, Marks GB, Eckhardt A, et al. The effect of respiratory activity, non-invasive 371 12 respiratory support and facemasks on aerosol generation and its relevance to COVID-19. 372 Anaesthesia 2021; 76: 1465–74. 373 374 13 Hamilton FW, Gregson F, Arnold DT, et al. Aerosol emission from the respiratory tract: an 375 analysis of relative risks from oxygen delivery systems. *medRxiv* 2021; : 376 2021.01.29.21250552. 377 14 Nissen K, Krambrich J, Akaberi D, et al. Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards. Sci Rep 2020; 10: 1–9. 378 379 15 UKHSA. Infection prevention and control for seasonal respiratory infections in health and care settings (including SARS-CoV-2) for winter 2021 to 2022. Updated 17 January 2022. 380 2022. https://www.gov.uk/government/publications/wuhan-novel-coronavirus-381 infection-prevention-and-control/covid-19-guidance-for-maintaining-services-within-382 health-and-care-settings-infection-prevention-and-control-383 recommendations#transmission-based-precautions. 384

It is made available under a CC-BY-NC-ND 4.0 International license .

385	16	Nightingale R, Nwosu N, Kutubudin F, et al. Is continuous positive airway pressure (CPAP)
386		a new standard of care for type 1 respiratory failure in COVID-19 patients? A
387		retrospective observational study of a dedicated COVID-19 CPAP service. BMJ Open
388		Respir Res 2020; 7 : 8–10.
389	17	Hadfield J, Megill C, Bell SM, et al. NextStrain: Real-time tracking of pathogen evolution.
390		Bioinformatics 2018; 34 : 4121–3.
391	18	World Health Organization. Modes of transmission of virus causing COVID-19:
392		implications for IPC precaution recommendations. Geneva World Heal Organ 2020; : 19-
393		21.
394	19	Chin AWH, Chu JTS, Perera MRA, et al. Stability of SARS-CoV-2 in different environmental
395		conditions. <i>The Lancet Microbe</i> 2020; 1 : e10.
396	20	Edwards T, Kay GA, Aljayyoussi G, et al. SARS-CoV-2 Transmission Risk from sports
397		Equipment (STRIKE). <i>medRxiv</i> 2021; : 2021.02.04.21251127.
398	21	Jeong GU, Yoon GY, Moon HW, et al. Comparison of plaque size, thermal stability, and
399		replication rate among SARS-CoV-2 variants of concern. <i>Viruses</i> 2022; 14 : 4–8.
400	22	R Core Team. R: A language and environment for ## statistical computing. 2017.
401	23	Chia PY, Coleman KK, Tan YK, et al. Detection of air and surface contamination by SARS-
402		CoV-2 in hospital rooms of infected patients. <i>Nat Commun</i> 2020; 11 .
403		DOI:10.1038/s41467-020-16670-2.
404	24	Santarpia JL, Rivera DN, Herrera VL, et al. Aerosol and surface contamination of SARS-
405		CoV-2 observed in quarantine and isolation care. Sci Rep 2020; 10. DOI:10.1038/s41598-
406		020-69286-3.
407	25	Li X, Ma X. Acute respiratory failure in COVID-19: Is it 'typical' ARDS? Crit Care 2020; 24:
408		1–5.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 26 Cevik M, Kuppalli K, Kindrachuk J, Peiris M. Virology, transmission, and pathogenesis of
 SARS-CoV-2. *BMJ* 2020; **371**: 1–6.
- 411 27 Lednicky JA, Lauzard M, Fan ZH, *et al.* Viable SARS-CoV-2 in the air of a hospital room
 412 with COVID-19 patients. *Int J Infect Dis* 2020; **100**: 476–82.
- Lednicky JA, Lauzardo M, Alam MM, *et al.* Isolation of SARS-CoV-2 from the air in a car
 driven by a COVID patient with mild illness. *Int J Infect Dis* 2021; **108**: 212–6.
- 415 29 Zhou J, Otter JA, Price JR, *et al.* Investigating Severe Acute Respiratory Syndrome
- 416 Coronavirus 2 (SARS-CoV-2) Surface and Air Contamination in an Acute Healthcare
- 417 Setting During the Peak of the Coronavirus Disease 2019 (COVID-19) Pandemic in 418 London. *Clin Infect Dis* 2021; **73**: e1870–7.
- Binder RA, Alarja NA, Robie ER et al. Environmental and aerosolized severe acute
 respiratory syndrome coronavirus 2 mong hospitalized coronavirus disease 2019
 patients. J Infect Dis 2020; 222: 1798–806.
- 422 31 Dumont-Leblond N, Veillette M, Mubareka S, *et al.* Low incidence of airborne SARS-CoV-
- 2 in acute care hospital rooms with optimized ventilation. *Emerg Microbes Infect* 2020; 9:
 2597–605.

425

It is made available under a CC-BY-NC-ND 4.0 International license .

427 Research in Context

428 Evidence before this study

We searched Pubmed (Medline, Web of science (Science citation index-Expanded and Biosis) and Embase for air sampling studies published between January 2020 and November 2021. Selected search terms were "COVID-19", "SARS-Cov-2", "air sampler", "indoor air quality", "bioaerosol" and "indoor airborne" with 326 results. Studies in which healthcare environments occupied by SARS-CoV-2 infected humans were sampled were eligible. After screening of abstracts and then full texts 37 papers were included.

Frequency of detection of viral RNA in air samples collected from COVID-19 patients varied 435 436 widely from 0% to 100% and factors affecting likelihood of positivity were not consistently 437 identified. Whilst isolation of infectious virus from air samples is not always attempted, it has only been reported twice but this reflect the challenges of fragile virus capture. Laboratory 438 439 studies have demonstrated that SARS-CoV-2 may persist for several hours in airborne particles, and epidemiological research has illustrated probable airborne transmission of COVID-19 in 440 settings such as restaurants. Observational data from the SARS-CoV-1 epidemic suggested that 441 aerosol generating procedures (AGPs) presented a greater transmission hazard than other care, 442 that required enhanced respiratory protection. Winslow et al recently reported that in a cohort 443 444 of 30 patients, that AGPs were not associated with increased likelihood of SARS-CoV-2 viral RNA detection in air compared to supplemental oxygen use. Studies of aerosol generation from 445 procedures such as CPAP and high flow oxygen on healthy volunteers in controlled 446 environments had predicted a low risk of airborne transmission related to such procedures in 447 comparison to cough, speech or singing. 448

449 Added value of this study

As the largest study to date to investigate SARS CoV-2 RNA detection in air samples from rooms of patients undergoing different interventions including AGPS this study contributes significantly to the limited evidence base in this area. We demonstrated that there was no greater frequency of detection of SARS-CoV-2 from the environment of patients undergoing AGPs compared to those on room air or oxygen. This suggests that the risk of aerosol transmission may be equally significant in all areas where COVID-19 patients are cared for and

456 appropriate respiratory precautions should be recommended. This important evidence can

457 provide data to support infection prevention and control guidance in health care settings and

- 458 inform risk assessments and the use of AGPs in all settings.
- 459

460 Implications of all available evidence

SARS CoV-2 virus has been identified in the air in a range of healthcare settings where COVID-19 patients are managed. Our findings in combination with those reported by Winslow et al suggest that AGPs do not present a uniformly increased transmission risk. Increased understanding of the natural history of COVID-19 and transmission characteristics of SARS-CoV-2, promote a move from the binary categories of AGP vs non-AGP for respiratory protection, towards a risk assessment based primarily on the Patient and Place, as opposed to just the procedure.

It is made available under a CC-BY-NC-ND 4.0 International license .

468 Appendix 1: Details of positive samples

469

Г

470 Positive samples - procedure, ventilation and Ct values

Ventilation: Negative pressure (ets. 12 ACH), Neutral or standard ward ventilation (est 6 ACH), ITU and theatre (est. 10 ACH)	Procedure: narrower categories	PCR result	Ngene	Sgene	ORF1
Negative	High flow	Positive	Negative	20.87	Negative
Negative	CPAP	Positive	32.16	Negative	38.35
Negative	CPAP	Positive	26.48	35.34	20.05
Neutral	Room air	Positive	Negative	38.76	25.37
Neutral	Room air	Positive	37.96	Negative	38.16
ITU	CPAP	Positive	Negative	Negative	37.65
Negative	Nasal cannulae	Positive	34.83	Negative	Negative
Negative	Room air	Positive	34.43	38.45	32.14
Negative	CPAP	Positive	38.46	Negative	Negative
Neutral	rebreathe mask	Positive	28.53	Negative	Negative
Neutral	Room air	Positive	33.17	Negative	Negative
Neutral	Nasal cannulae	Positive	33.03	Negative	Negative
Neutral	Room air	Positive	34.05	negative	34.16
Neutral	Venturi mask	Positive	32.25	Negative	34.71
Neutral	Nasal cannulae	Positive	30.78	Negative	Negative
Neutral	Nasai carinulae	Positive	32.32	Negative	35.91
Neutral	CPAP	Positive	Negative	Negative	37.51
Negative	CPAP	Positive	Negative	Negative	22.79
Negative	Venturi mask	Positive	35.31	Negative	Negative
Neutral	NK	Positive	32.52	Negative	33.04
Negative	Nasal cannulae	Positive	30.94	23.96	33.57
Negative	CPAP	Positive	Negative	Negative	33.4
Theatre	Endoscopy	Positive	Negative	32.97	19.39
Negative	Nasal cannulae	Positive	negative	27.7	Negative
Negative	Intubation	Positive	28.66	Negative	28.88
Negative	CPAP	Positive	28.9	Negative	Negative
Negative	Venturi mask	Positive	24.89	32.5	22.17
NK	Nasal cannulae	Positive	Negative	Negative	33.41
Neutral	Room air	Positive	Negative	20.47	Negative
Neutral	Room air	Positive	38.57	Negative	Negative
Neutral	Room air	Positive	33.47	Negative	36.14
Negative	CPAP	Positive	34.65	Negative	Negative
Negative	NK Manturi mask	Positive	35.73	Negative	Negative
NK	Venturi mask	Positive	35.18	Negative	Negative
Negative	Ventusi mesk	Positive	37.05	Negative	negative 36.17
Negative	Roomair	Positive	35.05	Negative	35.45
Negative	Room air	Positive	35.24	negative	negative
Negative	High flow	Positive	36.52	negative	negative
Negative	High flow	Positive	36.5	negative	negative
Neutral	Room air	Positive	32.53	negative	negative
Neutral	Room air	Positive	Negative	Negative	36.46
Theatre	Bronchoscopy	Positive	negative	negative	38.41
Theatre	Bronchoscopy	Positive	negative	negative	37.73
Negative	Room air	Positive	34.21	negative	negative
Negative	Room air	Positive	21.52	Negative	39.57
Negative	Room air	Positive	negative	negative	34
Negative	Venturi mask	Positive	35.29	Negative	35.78
Neutral	Venturi mask	Positive	31.07	Negative	35.54
Negative	CPAP	Positive	30.43	Negative	35.48
Negative	Venturi mask	Positive	36.01	Negative	36.4
Neutral	Nasal cannulae	Positive	32.41	Negative	34.4
Negative	Venturi mask	Positive	32.96	Negative	Negative

471

472 NK Not known CPAP Continuous positive airway pressure

It is made available under a CC-BY-NC-ND 4.0 International license .

474 Details of samples from other areas

Ventilation: Negative pressure (est. 12 ACH), Neutral or standard ward ventilation (est. 6 ACH), ITU and theatre (est. 10 ACH)	Setting	Area directly occupied or used by ISARS CoV-2 infected patients	PCR result	Ngene	Sgene	ORF1
ITU	Intubated patient	Yes	Positive	34.07	Negative	34.6
Neutral	Bathroom	Tes	Negative	Negative	Negative	Negative
Neutral	Bathroom	Yes	Positive	Negative	Negative	33.39
Neutral	Bathroom	Yes	Positive	34.89	Negative	Negative
Neutral	Bathroom	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Near air vent	No	Negative	Negative	Negative	Negative
Negative	Nurses station	No	Positive	23.72	22.4	33.57
Negative	Centre of bay	No	Negative	Negative	Negative	Negative
Negative	Centre of bay	No	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	Yes	Negative	Negative	Negative	Negative
Negative	Nurses station	No	Negative	Negative	Negative	Negative
Negative	Nurses station	No	Positive	35.19	negative	negative

475

It is made available under a CC-BY-NC-ND 4.0 International license .

477 Appendix 2: Review of previous air sampling studies

478 Summary of previous air sampling studies in healthcare settings which included details of

	Number o applicable	of samples, e)	AGPs and PCR					
Country	No. samples	No. patients	Air samples PCR positive/ suspect	Proportion patients with >/=1 positive sample	Culture attempted (Y/N)	Evidence of viable virus described	Description of AGPs	Proportion PCR positive (AGPs)
UK (refs)	4	4	2/4	NK	Y	N	Tracheosto my (3), HFNO (1)	2 (4)
USA	15	15	0/15	0(15)	N	N	BiPAP (2), HFNO (3)	0(5)
Israel	4	NK	1/4	n/a	N	N	>1 patient on high flow	1(1)
S Korea	6	3	0/6	0(3)	N	Ν	HFNO (1)	0(1)
Hong Kong	6	6	0/6	0(6)	N	N	HFNO (1)	0(1)
China	12	12	1/12	1(12)	N	N	intubation	1(1)
UK	90	30	14/90	9 (30)	Y	N	HFNO (30), CPAP (30)	9(60)

479 sampling around aerosol generating procedures (AGPs)

480 **PCR** polymerase chain reaction, **NK** not known, **n/a** not applicable, **HFNO** high flow nasal

481 oxygen, **CPAP** continuous, **AGP** Aerosol generating procedure

483 Summary of air sampling conducted 1) around specified numbers of SARS-CoV-2 infected patients, 2)

484 around unspecified numbers of infected patients and 3) in areas not occupied by COVID-19 patients

485 from studies where infected patients were also sampled

				Number of s amp	les, in dividuals (if	applicable) and re	sults of PCR and	culture (if applicat	ole)
			Country	No. samples	No. patients	Proportion air samples PCR positive/suspec t (all)	Proprtion patients with >/=1 positive sample	Culture attempted (Y/N)	Evidence of viable virus described
		Ong 2020	Singapore	6	3	0 (6)	0 (3)	N	N
		Semelka 2021	USA	78	26		0 (26)	N	N
2		Ong 2021	Singapore	12	19	6 (12)	NK	Y	N
atien		Wei 2020	China	34	9	0 (34)	0/9	N	N
ed pa		Binder 2020	USA	195	20	3(195)	3(20)	Y	N
fect		Guo 2020	China	48	39	15 (48)	NK	N	N
AD-19 in		Lednicky 2020	USA	4	2	4(4)	NK	Y	Y
	inic.	Faridi 2020	Iran	10	44	0(10)	NK (0)	N	N
f co'	orc	Dumont-Leblond	Canada	100	22	11(100)	6(22)	Y	N
o o	pital	Dubey 2021	In dia	24	12	17(24)	12 (12) at 1m, 5(N	N
dmu	Hos	Chia 2020	Singapore	22 pooled into 4	3	2(4)	2(3)	N	N
ц Б		Bokharaei-Salim 3	lran	14	16	0(14)	NK	N	N
ecifi		Baboli 2021	lran	29	25	4(29)	NK	N	N
d s þi		Santarpia 2020	USA	19	11	11(19)	8(11)	Y	Y
nour		Razzini 2020	Italy	2	3	2(2)	NK	N	N
ng a		Li 2020	China	14	9	2(14)	1(9)	N	N
đ		Lei 2020	China	36	20	0(36)	NK	N	N
З ^у		Jin 2021	China	1	1	1(1)	1(1)	N	N
	Quarantine	Ong 2021	Singapore	9	90	1 (9)	NK	Y	N
	facility or hotel	Ben-Shmuel 202	ls ra el	1	1	1(1)	1(1)	N	Ν
6	Hospital/clinic	Zhou 20 20	UK	22	n/a	11 (22)	n/a	Y	N
UD-1		Yuan 2020	China	32	n/a	0(32)	NK	Ν	Ν
Ô		Lednicky 2020	USA	2	NK	1(2)	n/a	Y	Y
er of		Li 2020	China	36	NK	0(36)	n/a	Ν	N
qun		Masoumbeigi 20	lran	30	NK	0(30)	NK	N	N
ed n nts		Kenarkoohi 2020	lran	11	NK	2(11)	NK	Ν	N
atie		Hernandez 2021	Mexico	10	n/a	3(10)	NK	N	N
dsun		Yuan 2020	China	11	n/a	8 (11)	NK	N	N
) pur		Ang 2021	Singapore	27	NK (wards full)	13(27)	NK	γ	Ν
arou		Barbieri 2021	Italy	6	NK	3 (6)	NK	N	Ν
oling		Dubey 2021	India	6	NK	5(6)	NK	N	Ν
lu s		Hemati 2021	lran	35	NK	5(35)	NK	N	N
		Grimalt 2021	Spain	11	NK	11(11)	NK	N	N
		Ong 2020	Singapore	4	n/a	0 (4)			
		Zhou 20 20	UK	5	n/a	1 (5)			
uals		Yuan 2020	China	58	n/a	0 (58)			
divid		Li 2020	China	99	n/a	0(99)			
d in		Masoumbeigi 20	lran	1	n/a	0(1)			
fecte	At ilia	Guo 2020	China	66	n/a	1 (66)			
vi v	ie fa	Kenarkoohi 2020	lran	3	n/a	0 (3)			
ied b	antir	Lane 2021	USA	528	n/a	0(528)			
dnoc	duar	Tan 2020	China	17	n/a	0(17)			
<u>^</u> 00	ō	Ben-Shmuel 202	ls ra el	1	n/a	0(1)			
irect	clinic	Hemati 2021	lran	10	n/a	1(10)			
ot o	iital/	Grimalt 2021	Spain	36	n/a	21 (36)			
eas	Hosp	Baboli 2021	Iran	22	n/a	2 (22)			
n ar	-	Dubey 2021	In dia	12	n/a	0(12)			
<u>п</u>		Yuan 2020	China	24	n/a	14(24)			
gung		Santarpia 2020	USA	16	n/a	11(16)			
U 3		Kazzini 2020	Italy	3	n/a	0(3)			
		Jin 2020	China	1	n/a	U(1)			
		Lei 2020	China	99	n/a	U(99)			